

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Glecaprevir-pibrentasvir for treating chronic hepatitis C

Batch 53

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

During the scoping process, it was noted that hepatitis C virus (HCV) disproportionately affects certain populations such as certain immigrant populations, prison populations, and drug users, which leads to poor quality care and potential discrimination in these groups.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Any recommendations on the use of glecaprevir-pibrentasvir would be irrespective of whether or not the person is in prison, or uses injectable drugs.

Related technology appraisals have already addressed the higher representation of minority ethnic groups in certain HCV genotypes, giving consideration to whether anything could be done to remove or reduce the disproportionate impact on the protected groups. The Committee may need to discuss similar equality issues for glecaprevir-pibrentasvir.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

Approved by Associate Director (name): Helen Knight

Date: 1/05/2017